Gatifloxacin
This broad-spectrum fluoroquinolone antibiotic inhibits bacterial DNA replication enzymes and is used to treat respiratory tract and eye infections. It is available as ophthalmic drops for bacterial conjunctivitis and was previously used orally until withdrawn from the systemic market due to blood sugar disturbances.
Peso molecular
375,4000 g/mol
LogP
-0,70
TPSA
82,10 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Estructura 2D
Cite this structure
Embed this structure
SMILES
COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
InChI
InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)
Molecular Formula
C19H22FN3O4
HBD / HBA
2 / 8
Enlaces Rotables
4
Átomos Pesados
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This broad-spectrum fluoroquinolone antibiotic inhibits bacterial DNA replication enzymes and is used to treat respiratory tract and eye infections. It is available as ophthalmic drops for bacterial conjunctivitis and was previously used orally until withdrawn from the systemic market due to blood sugar disturbances.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Yes, Gatifloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL31. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5379. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="gatifloxacin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/gatifloxacin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/gatifloxacin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/gatifloxacin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="gatifloxacin"></drugfyi-drug>